肾糖康合剂联合西药治疗早期糖尿病肾病的临床研究

Clinical study of renal glucose kang mixture combined with western medicine in the treatment of early diabetic nephropathy

目的观察肾糖康合剂对早期糖尿病肾病(diabetic nephropathy,DN)的临床疗效。方法将符合纳入标准的40例早期DN患者随机分为治疗组和对照组各20例,2组均予控制饮食、降糖等基础治疗,同时给予福辛普利每日1次,连服2月;治疗组在此基础上口服肾糖康合剂,每日1剂,每次300 ml,早晚各服1次,连服2月。结果治疗组尿微量白蛋白/肌酐比值(Alb/Cr)和超敏C反应蛋白(hsCRP)水平显著优于对照组,二者具有统计学差异。结论肾糖康合剂可以改善早期DN患者临床症状,减少尿微量白蛋白排泄,降低hsCRP从而改善慢性炎症。

Objective To observe the clinical effect of renal glucose kang mixture on early diabetic nephropathy （DN）. Methods A total of 40 patients with early DN were randomly divided into treatment group（n=20） and control group（ n= 20）. Two groups were given the diet and hypoglycemie therapy, meanwhile they were given Fosinopril sodium tablets one time a day, continuously for two months ; The treatment group was given the oral renal glucose kang mixture with one agent a day and 300 ml each time, continuously for two months. Results After the treatment, the outcome of treat- ment group in reducing urinary mieroalbumin/ereatinine and high sensitive C reactive protein was statistically better than that of control group. Conclusions renal glucose kang mixture can improve the clinical symptoms of patients with early DN, through reducing urinary microalbumin/ereatinine and lowering high sensitivity C reactive protein that is related to clinical inflammation.